Print

BG Medicine (BGMD) Highlights Role of Galectin-3 Testing in Combating Hospital Readmissions at the American College of Cardiologyy's (ACC) 62nd Annual Scientific Session & Expo  
3/6/2013 11:10:24 AM

WALTHAM, Mass., March 6, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a diagnostics company focused on the development and commercialization of novel cardiovascular tests, today announced that company representatives and independent researchers will highlight the clinical utility of galectin-3 blood testing in assessing the prognosis of patients with chronic heart failure through an extensive series of data presentations and company-sponsored events at the American College of Cardiology's (ACC) 62nd Annual Scientific Session & Expo in San Francisco, California.
//-->